ClinicalTrials.gg
RecruitingNCT07687784Updated Nov 20, 2026

A Study to Test the Non-Inferiority of Ferric Bepectate IV Against Ferric Carboxymaltose in Patients With Iron Deficiency Anemia

A Phase 3 interventional study of Ferric Bepectate IV Injection and Ferric Carboxymaltose Injection [Ferinject] in Iron Deficiency Anemia (IDA), sponsored by AFT Pharmaceuticals, Ltd.. Recruiting at 24 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by AFT Pharmaceuticals, Ltd. · Phase 3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Now RecruitingFirst site in New Zealand+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,366
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 134 studies in Anemia, Iron-Deficiency with a site in United States — 18 open to participants now, 21 under way, 7 of them phase 3. Anemia, Iron-Deficiency · United States.

Planned enrollment
8th of 121
1,366 · median 51
Started
2026
with 5 others
Phase 3
35 of 134
7 open now
Primary completion
2028-06
later than 15 of 20 live
Registered
130th of 134
by date

Among the 134 studies in Anemia, Iron-Deficiency with a site in United States, this one is the 8th largest by planned enrollment of the 121 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 in phase 3, reaches primary completion later than 15 of the 20 other live ones, and was the 130th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

18 of the 134 studies in Anemia, Iron-Deficiency with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Anemia, Iron-Deficiency with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to see if a new intravenous iron formulation (Ferric Bepectate IV Injection) can treat adult patients with iron deficiency anemia (IDA) by increasing blood hemoglobin (Hb) as an established formulation (Ferric carboxymaltose). It will also learn about the safety of Ferric Bepectate IV Injection. The main questions it aims to answer are:

  • Does hemoglobin increase by the same amount 6 weeks after each treatment?
  • What medical problems do participants have when being treated with the drug? Researchers will compare single dose treatment plans of Ferric Bepectate to double dose treatment plans of both Ferric Bepectate and Ferric carboxymaltose.

Participants and researchers will know which drug they are being provided (open-label). Participants will visit the clinic 5 times over 6 weeks for checkups, blood tests and questionaries. The first two visits will be seven days apart and include the two doses of iron treatment.

Read the detailed description

Iron is essential for the normal functioning of a human body. Iron deficiency anemia (IDA) occurs when blood lacks adequate healthy red blood cells, preventing adequate distribution of oxygen throughout the tissue of the body.

IDA, if left uncorrected, may result in complications such as extreme fatigue, weakness, chest pain, shortness of breath, irregular heartbeats or even heart failure in some cases, in addition to reducing the overall quality of life of a patient. Iron supplementation can effectively treat IDA. An iron-rich diet is known to enhance iron levels, however supplementation is limited by the bio-availability of iron compounds. Oral iron treatment is the most common form of therapy for iron supplementation. However, oral iron supplementation is not ideal for all patients, as adverse events are common, and some patients also fail to respond. Common adverse events (AEs) include significant gastrointestinal discomfort, metallic taste and staining of teeth, resulting in patience discontinuing the treatment. Intravenous (i.v) iron therapy is regarded as a safe method to correct anemia resulting from several conditions that avoids many of the gastrointestinal AEs common with oral iron supplementation.

Ferric carboxymaltose is an established i.v iron formulation approved to treat IDA in Europe and USA. In patients with high iron need, ferric carboxymaltose requires at least two injections, at least 7 days apart. A new i.v. iron formulation has been developed, Ferric Bepectate IV Injection. Ferric Bepectate IV Injection has the potential to be dosed at higher volumes compared to other i.v. iron formulations, allowing for patients with high iron needs to only undergo a single infusion, reducing the medical burden on both the patient and the medical system, and providing a rapid improvement to IDA and associated symptoms.

The current phase 3 study aims to compare Ferric Bepectate IV Injection with two Ferric carboxymaltose formulations (comparators: Ferinject® and Injectafer®) to determine non-inferiority between the Ferric Bepectate IV Injection single dose administration and the current approved dosing for the comparators. A comparison between treatments of the change of hemoglobin (Hb) from baseline after 6 weeks will be the primary outcome. Safety of each treatment will also be assessed to determine superiority, by examining the number of adverse events in the 2 hour period following the beginning of infusion. Key secondary safety endpoints will assess the difference in volume-corrected urine iron after i.v administration, and incidence of hypophosphatemia during the 6 week follow-up period.

A two-dose administration of Ferric Bepectate IV Injection will also be assessed to compare efficacy, tolerance, and safety with the single-dose administration and the comparators.

03

Conditions studied

  • Iron Deficiency Anemia (IDA)

Keywords

  • Iron infusion
  • Non-inferiority
  • Ferric bepectate
  • Ferric carboxymaltose
  • Ferinject
  • Injectafer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patient at least 18 years old at the time of screening
  2. Patients with general iron deficiency anaemia IDA
  3. Patients with serum ferritin levels ≤40 ng/mL inclusive
  4. Patients with (Hb) levels \<10 g/dL
  5. Patients ≥ 35 kg body weight
  6. The patient has adequate hepatic and renal function defined as a serum or alanine aminotransferase level that are no more than 3 times the , a serum level that is no more than 2 times the upper limit of the normal range and a serum creatinine level of less than 2 mg/dL.
  7. The patient is able to understand the protocol and provides to participate in the study

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding patients
  2. Female patients not willing to use a safe method of (PEARL index \<1) for the full study (screening - V5).
  3. Severe physical inability, e.g., IV or V.
  4. Non-iron deficiency anaemia, e.g., known Vitamin B12 or folate deficiency, hemoglobinopathy, or unexplained anaemia.
  5. Patients with life-threatening anaemia, defined as \< 6.5 g/dL.
  6. Patient is expected to require a blood transfusion within the study period or has had a blood transfusion within the 30 days prior screening.
  7. Anticipated medical need for erythropoiesis-stimulating agents during the study period (screening - V5).
  8. Patients with hemodynamic instability due to any ongoing bleeding. Absence of ongoing bleeding will be confirmed either by decision of two independent physicians or by removal of drainage whichever occurs earlier in routine care.
  9. Patient has undergone a surgical procedure during the 30 days prior to screening, and/or is expected to undergo a surgical procedure during the study period (screening - V5).
  10. Patients with any to the products, e.g.,

    1. known sensitivity to iron or an ingredient of the investigational products,
    2. significant history of systemic allergic reactions,
    3. hemochromatosis, thalassemia or TSAT >50% as indicator of iron overload,
    4. acute or chronic intoxication,
    5. infection (patient on non-prophylactic antibiotics),
    6. chronic liver disease and/or screening or AST above three times the .
    7. chronic kidney disease, defined as \<30 mL/min.
  11. Primary hematologic disease.
  12. Drug or alcohol abuse according to WHO definition.
  13. Potentially unreliable patients, and those judged by the investigator to be unsuitable for the study.
  14. Current or previous participation in another clinical trial during the last 90 days before screening.
  15. Exclusion criteria according to SmPC of Ferric Carboxymaltose.
  16. The following concomitant treatments prescribed by a physician for non-iron deficiency anaemia (e.g., known vitamin B12 or folate deficiency), hemoglobinopathy, or unexplained anaemia are not allowed during the study and 24 weeks before screening: Erythropoiesis-stimulating agents, vitamin B12, Folic acid or other I.V. or oral iron products.
  17. Estimated of \<6 months or, for cancer patients, an performance status >1
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,366 participants (estimated)

Study arms

  • Experimental
    Ferric Bepectate IV Injection single dose (US/Japan)

    Single dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 2000 mg per dose.

    Drug: Ferric Bepectate IV Injection

  • Experimental
    Ferric Bepectate IV Injection single dose (RoW)

    Single dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 2000 mg per dose.

    Drug: Ferric Bepectate IV Injection

  • Experimental
    Ferric Bepectate IV Injection two doses (US/Japan)

    Two dose experimental treatment arm for USA and Japan. 50 mg iron/mL. Up to 1000 mg per dose.

    Drug: Ferric Bepectate IV Injection

  • Experimental
    Ferric Bepectate IV Injection two doses (RoW)

    Two dose experimental treatment arm for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.

    Drug: Ferric Bepectate IV Injection

  • Active comparator
    Injectafer (US/Japan)

    Two dose ferric carboxymaltose active comparator treatment for USA and Japan. 50 mg iron/mL. Up to 750 mg per dose.

    Drug: Ferric Carboxymaltose Injection [Injectafer®]

  • Active comparator
    Ferinject (RoW)

    Two dose ferric carboxymaltose active comparator treatment for rest of world. 50 mg iron/mL. Up to 1000 mg per dose.

    Drug: Ferric Carboxymaltose Injection [Ferinject]

Interventions

06

What researchers measure

Primary outcomes

  1. Change in hemoglobin comparing one dose Ferric bepectate and two dose Injectafer treatment

    The mean change in blood hemoglobin from baseline at week 6 showing non-inferiority between the treatment groups Ferric Bepectate IV Injection (single dose) and Injectafer

    Time frame: 6 weeks

  2. Change in hemoglobin comparing one dose Ferric bepectate and two dose Ferinject treatment

    The mean change in blood hemoglobin from baseline at week 6 showing non-inferiority between the treatment groups Ferric Bepectate IV Injection (single dose) and Ferinject

    Time frame: 6 weeks

  3. Incidence of treatment emergent adverse events

    Incidence of treatment emergent adverse events (TEAE) during the 2 hours following the start of infusion

    Time frame: 2 hours post infusion start

Secondary outcomes

  1. Blood hemoglobin amount

    Mean blood hemoglobin at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.

    Time frame: 6 weeks

  2. Hemoglobin change from baseline

    Mean change in blood hemoglobin from baseline to weeks 1, 2, 4 and 6.

    Time frame: 6 weeks

  3. Serum iron change from baseline

    Mean change in serum iron from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.

    Time frame: 6 weeks

  4. Serum ferritin change from baseline

    Mean change in serum ferritin from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.

    Time frame: 6 weeks

  5. Serum transferrin change from baseline

    Mean change in serum transferrin from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.

    Time frame: 6 weeks

  6. Serum transferrin saturation change from baseline

    Mean change in serum transferrin saturation (TSAT) from baseline at weeks 1, 2, 4 and 6 timepoints. Compared between all treatment groups.

    Time frame: 6 weeks

  7. Response Rate

    Proportion of patients with normalization (defined in WHO classification) of hemoglobin at week 6 (Response Rate).

    Time frame: 6 weeks

  8. Time to normalization of hemoglobin

    Time to normalization normalization (defined in WHO classification) of hemoglobin at week 6 (Response Rate).

    Time frame: 6 weeks

  9. Change in fatigue symptoms

    Change in fatigue symptoms from baseline at week 6 measured by the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue). A final score of 0-52 is calculated, where a high score indicates better quality of life.

    Time frame: 6 weeks

  10. Incidence of hypophosphatemia

    Incidence of hypophosphatemia (serum phosphate \< 2 mg/dL) at any time during the follow-up period (baseline - week 6)

    Time frame: 6 weeks

  11. Volume-corrected urine iron amount

    Pre- and post-difference of volume-corrected urine iron levels measured before and in the first urine after the end of i.v. administration, (volume corrected iron urine is defined as the ratio between urine iron and urine creatinine)

    Time frame: 2 hours

  12. Adverse event severity

    Severity of treatment emergent adverse events (TEAEs) during the 2 hours following infusion start

    Time frame: 2 hours following infusion start

  13. Adverse event incidence and severity

    Incidence and severity of TEAEs during the entire study period (screening - V5)

    Time frame: 6 weeks

  14. Treatment related adverse event incidence and severity

    Incidence and severity of AEs classified as possibly, probably or definitely related to the study drug (Treatment related adverse events; TRAE) during the study period (screening - V5)

    Time frame: 6 weeks

  15. Incidence of injection/infusion site reactions and hypersensitivity reactions

    Incidence of injection/infusion site reactions and hypersensitivity reactions

    Time frame: 2 hours following infusion start

  16. Change in serum phosphate

    Mean change in serum phosphate from baseline to week 6

    Time frame: 6 weeks

  17. Change in serum calcium

    Mean change in serum calcium from baseline to week 6

    Time frame: 6 weeks

  18. ECG changes

    Electrocardiogram (ECG) changes from baseline at week 1, 2, 4 and 6. The ECG will specifically assess the following parameters: * Heart Rate * QT interval * ST depression * T wave inversion * Prescence of tachycardia * Left ventricular hypertrophy * Investigator interpretation (normal, abnormal NCS, abnormal CS)

    Time frame: 6 weeks

  19. ECG and Hemoglobin relationship

    Relation between electrocardiogram (ECG) investigator interpretation (normal, abnormal NCS, abnormal CS) and hemoglobin at baseline and End of Treatment

    Time frame: 6 weeks

Other outcomes

  1. Pooled data hemoglobin amount

    Mean hemoglobin at weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  2. Pooled data change in hemoglobin

    Mean change in hemoglobin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  3. Pooled data change in serum iron

    Mean change in serum iron from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  4. Pooled data change in serum ferritin

    Mean change in serum ferritin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  5. Pooled data change in serum transferrin

    Mean change in serum transferrin from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  6. Pooled data change in serum transferrin saturation

    Mean change in serum transferrin saturation (TSAT) from baseline to weeks 1, 2, 4 and 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  7. Proportion of patients requiring blood transfusion

    Proportion of patients who require red blood cell transfusion up to week 6. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

  8. Duration of hospital stay

    Duration of hospital stay (days), if applicable. Pooled data (USA+Japan+RoW) between study regions.

    Time frame: 6 weeks

07

Study locations

15 of 24 sites recruiting
  • Trialmed Phoenix
    Phoenix, Arizona 85020, United States
    Recruiting
    • Fiona Marquez · Contact877-469-4154
    • Shawn Searle · Principal investigator
  • PharmaSouth Research
    Coral Gables, Florida 33146, United States
    Recruiting
    • Adrian Landrian · Contactinfo@pharmasr.com · 305-280-7305
    • Francisco Quintana, MD · Principal investigator
  • M3 Wake Research - Lake City
    Lake City, Florida 32055, United States
    Recruiting
  • Trialmed Melbourne
    Melbourne, Florida 32934, United States
    Recruiting
  • Trialmed The Villages
    The Villages, Florida 32162, United States
    Recruiting
    • Stephanie Smith · Contact352-361-0901
    • Angela Okolie, MD · Principal investigator
  • Trialmed Evansville
    Evansville, Indiana 47714, United States
    Recruiting
  • Ingham Nephrology & Hypertension, P.C.
    Lansing, Michigan 48911, United States
    Recruiting
    • Victor Sandoval · Contactinfo@inghamneph.com · 517-485-8217
    • Brian Cousino · Principal investigator
  • Brookhaven Heart
    Patchogue, New York 11772, United States
    Recruiting
  • Trialmed Asheboro
    Asheboro, North Carolina 27203, United States
    Recruiting
  • M3 Wake Research - Raleigh
    Raleigh, North Carolina 27612, United States
    Recruiting
  • M3 Wake Research - Charleston
    Charleston, South Carolina 29414, United States
    Recruiting
  • Trialmed Austin
    Austin, Texas 78744, United States
    Recruiting
  • M3 Wake Research
    Dallas, Texas 75246, United States
    Recruiting
  • PatientCare Clinical Research
    Houston, Texas 77075, United States
    Recruiting
  • Trialmed San Antonio
    San Antonio, Texas 78229, United States
    Recruiting
  • Medical Center Levitas EOOD
    Sofia, Bulgaria
    Not yet recruiting
    • Boris Krumov, MD · Principal investigator
  • Momentum West Auckland
    Auckland, 0600, New Zealand
    Not yet recruiting
    • Jean Gao · Contactjean.gao@momcr.co.nz · +649 883 0123
    • Milan Radojevic · Principal investigator
  • Momentum Waikato
    Hamilton, 3200, New Zealand
    Not yet recruiting
  • Momentum Hutt Valley
    Upper Hutt, 5018, New Zealand
    Not yet recruiting
  • Szpital AidPort
    Skórzewo, Poland
    Not yet recruiting
    • Michal Kwiatek, MD · Principal investigator
  • Ames Medical Research
    Bragadiru, Romania
    Not yet recruiting
    • Carastoian Nicoleta, MD · Principal investigator
  • Colentina Clinical Hospital
    Bucharest, Romania
    Not yet recruiting
    • Daniela Georgescu, MD · Principal investigator
  • Sana Medical Center
    Bucharest, Romania
    Not yet recruiting
    • Adrian Sarbu, MD · Principal investigator
  • The Oncology Institute
    Cluj-Napoca, Romania
    Not yet recruiting
    • Ciprian Tomuleasa, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided — The results of the study may be published in a scientific journal, however individual patient data will not be used, rather data will be provided as descriptive statistics (mean, median, IQR) as required.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's planned 19 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Dec 2026 → Nov 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2026
First posted
Jul 7, 2026
StartEst.
Nov 2026was Dec 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jul 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 20, 2026
Sites
12 sites added, 1 site removed — first site in New Zealand. 12 sites changed recruiting status (6 now recruiting, 6 now not yet recruiting)
Show 12 sites
  • PharmaSouth Research · Coral Gables, United Statesno status→Recruiting
  • Trialmed Melbourne · Melbourne, United Statesno status→Recruiting
  • Trialmed The Villages · The Villages, United Statesno status→Recruiting
  • M3 Wake Research · Dallas, United Statesno status→Recruiting
  • PatientCare Clinical Research · Houston, United Statesno status→Recruiting
  • Trialmed San Antonio · San Antonio, United Statesno status→Recruiting
  • Medical Center Levitas EOOD · Sofia, Bulgariano status→Not yet recruiting
  • Szpital AidPort · Skórzewo, Polandno status→Not yet recruiting
  • Ames Medical Research · Bragadiru, Romaniano status→Not yet recruiting
  • Colentina Clinical Hospital · Bucharest, Romaniano status→Not yet recruiting
  • Sana Medical Center · Bucharest, Romaniano status→Not yet recruiting
  • The Oncology Institute · Cluj-Napoca, Romaniano status→Not yet recruiting
Show 12 added (9 United States, 3 New Zealand)
  • Trialmed Phoenix · Phoenix, United States
  • M3 Wake Research - Lake City · Lake City, United States
  • Trialmed Evansville · Evansville, United States
  • Ingham Nephrology & Hypertension, P.C. · Lansing, United States
  • Brookhaven Heart · Patchogue, United States
  • Trialmed Asheboro · Asheboro, United States
  • M3 Wake Research - Raleigh · Raleigh, United States
  • M3 Wake Research - Charleston · Charleston, United States
  • Trialmed Austin · Austin, United States
  • Momentum West Auckland · Auckland, New Zealand
  • Momentum Waikato · Hamilton, New Zealand
  • Momentum Hutt Valley · Upper Hutt, New Zealand
Show 1 removed
  • Olympus Clinical Research · Sugar Land, United States
Nov 20, 2026
Start date
Dec 2026→Nov 2026
Nov 20, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • PharmaSouth Research · Coral Gables, United StatesContact added i•••@pharmasr.com · •••7305
  • Trialmed Melbourne · Melbourne, United StatesContact added n•••@trialmed.com · •••2638
  • Trialmed The Villages · The Villages, United StatesContact added •••0901
  • M3 Wake Research · Dallas, United StatesContact added v•••@wakeresearch.com · •••3074
  • PatientCare Clinical Research · Houston, United StatesContact added m•••@patientcareclinicalresearch.com · •••7467
  • Trialmed San Antonio · San Antonio, United StatesContact added e•••@trialmed.com · •••7483
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    Not yet recruiting→Recruiting
    12 sites added, 1 site removed — first site in New Zealand. 12 sites changed recruiting status (6 now recruiting, 6 now not yet recruiting)
    Show 12 sites
    • PharmaSouth Research · Coral Gables, United Statesno status→Recruiting
    • Trialmed Melbourne · Melbourne, United Statesno status→Recruiting
    • Trialmed The Villages · The Villages, United Statesno status→Recruiting
    • M3 Wake Research · Dallas, United Statesno status→Recruiting
    • PatientCare Clinical Research · Houston, United Statesno status→Recruiting
    • Trialmed San Antonio · San Antonio, United Statesno status→Recruiting
    • Medical Center Levitas EOOD · Sofia, Bulgariano status→Not yet recruiting
    • Szpital AidPort · Skórzewo, Polandno status→Not yet recruiting
    • Ames Medical Research · Bragadiru, Romaniano status→Not yet recruiting
    • Colentina Clinical Hospital · Bucharest, Romaniano status→Not yet recruiting
    • Sana Medical Center · Bucharest, Romaniano status→Not yet recruiting
    • The Oncology Institute · Cluj-Napoca, Romaniano status→Not yet recruiting
    Show 12 added (9 United States, 3 New Zealand)
    • Trialmed Phoenix · Phoenix, United States
    • M3 Wake Research - Lake City · Lake City, United States
    • Trialmed Evansville · Evansville, United States
    • Ingham Nephrology & Hypertension, P.C. · Lansing, United States
    • Brookhaven Heart · Patchogue, United States
    • Trialmed Asheboro · Asheboro, United States
    • M3 Wake Research - Raleigh · Raleigh, United States
    • M3 Wake Research - Charleston · Charleston, United States
    • Trialmed Austin · Austin, United States
    • Momentum West Auckland · Auckland, New Zealand
    • Momentum Waikato · Hamilton, New Zealand
    • Momentum Hutt Valley · Upper Hutt, New Zealand
    Show 1 removed
    • Olympus Clinical Research · Sugar Land, United States
    Start date Dec 2026→Nov 2026
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • PharmaSouth Research · Coral Gables, United StatesContact added i•••@pharmasr.com · •••7305
    • Trialmed Melbourne · Melbourne, United StatesContact added n•••@trialmed.com · •••2638
    • Trialmed The Villages · The Villages, United StatesContact added •••0901
    • M3 Wake Research · Dallas, United StatesContact added v•••@wakeresearch.com · •••3074
    • PatientCare Clinical Research · Houston, United StatesContact added m•••@patientcareclinicalresearch.com · •••7467
    • Trialmed San Antonio · San Antonio, United StatesContact added e•••@trialmed.com · •••7483

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07687784
Lead sponsor
AFT Pharmaceuticals, Ltd.
Collaborators
HungaroTrial
Responsible party
Sponsor
First posted
Jul 7, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Phillip Aitken, PhD
Contact
phillip.aitken@aftpharm.com
+6494880232
Ioana Stanescu, Phil.Lic., MSc.
study director · AFT Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric bepectate

Start the discussion